The study concluded that in tumors, such as melanoma and renal clear cell carcinoma, individuals with somatic PBRM1 mutations have increased sensitivity to treatment with PD1/PDL1 inhibitors, which might be associated with aberrant chromosomal methylation and TNF-α release. This evidence concerns the gene PBRM1 and melanoma.